Search

Researchers from Syqe Medical Ltd. have submitted a patent application for a controlled release system for substances from a source material. The patent application includes information on the optimal storage conditions for preserving the composition of naturally biosynthesized secondary metabolites in cannabis inflorescences and extracts. It also describes a source material cartridge for use with a personal inhaler device, which includes sensors for monitoring storage conditions and a logger to record the data. The patent application describes methods and devices for controlled release of substances from a source material, particularly for inhalation, and provides detailed claims and additional information for further reference. [Extracted from the article]

Geneos Therapeutics has announced positive results from its GT-30 clinical trial of a personalized therapeutic cancer vaccine (PTCV) in combination with pembrolizumab, a PD-1 inhibitor, for patients with advanced hepatocellular carcinoma (HCC). The trial met its primary endpoints of safety and immunogenicity, with PTCV-related adverse events limited to Grades 1 and 2. The observed response rate (ORR) for the combination therapy was 30.6%, including three complete responses and eight partial responses, which is statistically significant compared to pembrolizumab monotherapy. The study also demonstrated the induction of new T cell responses to vaccine-encoded neoantigens, suggesting the potential of personalized cancer vaccines for enhancing clinical response to anti-PD-1 therapy. [Extracted from the article]

A research paper titled "Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia" was recently published in Oncotarget's Volume 15. The paper investigates the potential of the growth hormone-releasing hormone (GHRH) receptor antagonist MIA-602 as a treatment for Doxorubicin-resistant acute myeloid leukemia (AML). The study found that MIA-602 significantly reduced cell viability in both wild-type AML cells and Doxorubicin-resistant clones. In an in vivo experiment using xenografted mice, MIA-602 treatment resulted in a reduction in tumor volume compared to the control group. The researchers suggest that GHRH antagonists like MIA-602 may offer an alternative treatment approach for AML and drug-resistant AML, potentially avoiding the side effects associated with standard chemotherapy. [Extracted from the article]

BrainStorm Cell Therapeutics Inc. has announced the publication of Phase 3 biomarker data in Muscle and Nerve. The study suggests that their investigational cell therapy, debamestrocel or NurOwn, may impact key biomarkers in amyotrophic lateral sclerosis (ALS) that are predictive of disease progression. The study analyzed forty-five biomarkers and identified three that are predictive of clinical outcomes in debamestrocel-treated participants. Treatment with debamestrocel led to significant changes in 64% of the analyzed biomarkers, indicating potential benefits for patients with ALS. [Extracted from the article]

Baxter International Inc. has been granted a patent for containers with selective dissolved gas content, specifically designed for parenteral nutrition products. The patent focuses on maintaining the stability and potency of oxygen-sensitive compounds by controlling the presence of gases, such as oxygen, in the containers. The containers are made of film materials with high gas-barrier properties and are filled with a selective dissolved gas based on the compound's requirements. The patent also discusses the importance of reducing headspace and the challenges associated with stability. Overall, the patent addresses the technical aspects of container design and gas control in the context of pharmaceutical solutions. [Extracted from the article]

A patent has been issued for an endotracheal tube holder device by Teleflex Medical Incorporated. The device is designed to secure and stabilize endotracheal tubes, which are used to deliver air to patients who cannot breathe on their own. The device includes a support rail, an auxiliary clip for holding accessory devices, and a tube fastener for securing the endotracheal tube. The invention aims to improve the comfort and stability of endotracheal tube placement for patients. [Extracted from the article]

A patent has been issued for an electrosurgical pencil by Stryker European Operations Limited. The pencil is used in surgery for cutting tissue and coagulating blood. It includes a telescoping function that allows for variable length without replacing the electrode. The pencil also has a smoke evacuation shroud to reduce smoke generation during surgery. The patent provides detailed descriptions and claims for the design and operation of the pencil. [Extracted from the article]

C.R. Bard Inc. has been granted a patent for a catheterization package that aims to improve the accuracy of diagnosing catheter-associated urinary tract infections (CAUTI) and reduce the risk of contamination. The package includes a urinary catheter, a urine-drainage bag, and a sampling-port access device, all held in a catheterization tray. The patent provides detailed descriptions of the components and step-by-step instructions for the catheterization procedure. NewsRx LLC is a reliable source for fact-based news on various topics, including C.R. Bard Inc., catheterization, and healthcare technology companies, making it a valuable resource for library patrons conducting research in a culturally sensitive and respectful manner. [Extracted from the article]

A patent application has been made available online for a laser system and method designed to detect and process information related to glaucoma. Glaucoma is a leading cause of irreversible blindness worldwide, affecting over 80 million people. The current treatments for glaucoma have limitations and complications, and none can treat low IOP glaucoma. The laser system described in the patent application aims to change intraocular pressure (IOP) in real-time based on detected information about the eye. The system can be operated by a medical practitioner who selects the laser mode and starts the treatment, which can automatically stop or pause when a predetermined threshold is reached. The patent application describes a laser system that includes a laser source, a feedback controller, a first optical delivery element, and a detecting element. The feedback controller regulates the dosimetry of the laser source based on real-time information detected by the detecting element. The system can be used to modify a porous structure on the sclera, measure mechanical characteristics of the cornea, and activate cells on the ciliary body. The feedback controller can be connected to a high-performance computer or a quantum computer for processing the detected information. [Extracted from the article]

A recent report from Janssen Research & Development LLC discusses the use of adeno-associated virus (AAV) vector-based gene therapy for treating diseases by modifying or replacing defective genes. The eye is considered an attractive target for gene therapy due to its accessibility and low risk of systemic side effects. The report addresses challenges and scientific questions related to the clinical development of AAV-based retina gene therapy, including dose selection, bioanalytical assays, trial design, immunogenicity, and regulatory perspectives. The information presented aims to guide the clinical development strategy for retina gene therapy, with a focus on clinical pharmacology. [Extracted from the article]

A patent has been issued for a medical information lookup patch and method. The patch is designed to provide easily accessible and personalized recovery information for patients who have undergone surgery. It includes a substrate with different information areas, such as brand information, instructive information, and lookup information. The lookup information contains a machine-readable code that, when processed by a machine, directs the machine to display human-readable information. The method involves providing a web server, contracting with a health worker to distribute the patch, collecting contact and medical care information, building a microsite, encoding lookup instructions, and distributing the patch to patients. The patch can be applied to a medical device, and patients can read the machine-readable code with a machine to access the relevant information. The patent was filed by DJO LLC and published in March 2024. [Extracted from the article]

A research paper published in Aging suggests that chlorogenic acid, a major polyphenol found in Du-Zhong, a herb used in Traditional Chinese Medicine, may be a promising candidate for the treatment of osteoporosis. The study found that chlorogenic acid enhanced osteoblast functions and suppressed osteoclast formation, effectively preventing bone loss in ovariectomized rats. The researchers concluded that chlorogenic acid could potentially be developed into a novel anti-osteoporosis treatment. [Extracted from the article]

A recent study examines the role of the World Organisation for Animal Health (WOAH) in global wildlife disease surveillance. WOAH's mission is to ensure transparency of the global animal health situation. The organization collects data on wildlife diseases, with 154 countries reporting 68,862,973 cases in the most recent years. However, challenges to wildlife disease surveillance remain, and a cross-sectoral collaboration is needed to improve surveillance sensitivity and safeguard wildlife population health and biodiversity conservation. For more information, readers can refer to the journal article "Role of the World Organisation for Animal Health in global wildlife disease surveillance" published in Frontiers in Veterinary Science. [Extracted from the article]

A research paper published in Oncotarget's Volume 15 explores the synergistic cytotoxicity of ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, with the DNA alkylator thiotepa (Thio) in acute myeloid leukemia (AML) cells. The study demonstrates that the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of fludarabine, cladribine, and busulfan in AML cell lines and leukemia patient-derived cell samples. The results suggest that this combination could be used in clinical trials as part of pre-transplant conditioning regimens for AML patients undergoing hematopoietic stem cell transplantation (HSCT). The study also indicates the potential clinical relevance of the combination in overcoming ABT199/venetoclax resistance and its activity against certain cell lines. [Extracted from the article]